{"id":"concurrent-lenvatinib","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Hypertension"},{"rate":"35-45","effect":"Diarrhea"},{"rate":"30-40","effect":"Fatigue"},{"rate":"25-35","effect":"Decreased appetite"},{"rate":"20-30","effect":"Nausea"},{"rate":"20-25","effect":"Proteinuria"},{"rate":"15-25","effect":"Weight loss"},{"rate":"10-20","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lenvatinib inhibits multiple receptor tyrosine kinases involved in tumor angiogenesis and proliferation, including fibroblast growth factor receptors (FGFR1-4), vascular endothelial growth factor receptors (VEGFR1-3), RET proto-oncogene, and KIT. By blocking these pathways, it reduces tumor blood vessel formation and directly suppresses cancer cell growth. The 'concurrent' designation suggests this is being studied in combination with another therapeutic agent.","oneSentence":"Lenvatinib is a multi-targeted tyrosine kinase inhibitor that blocks FGFR, VEGFR, RET, and KIT signaling to inhibit tumor angiogenesis and growth.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:07:26.094Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced hepatocellular carcinoma (in combination therapy)"},{"name":"Differentiated thyroid cancer"},{"name":"Renal cell carcinoma (in combination therapy)"}]},"trialDetails":[{"nctId":"NCT07480382","phase":"NA","title":"Safety and Efficacy of LVD + C-TACE + Tis/Len for Unresectable Right-Liver HCC","status":"NOT_YET_RECRUITING","sponsor":"Hong Wu","startDate":"2026-04-01","conditions":"Initially Unresectable Hepatocellular Carcinoma","enrollment":30},{"nctId":"NCT07381634","phase":"PHASE2","title":"The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2026-03-20","conditions":"Hepatocellular Carcinoma (HCC), IrAE","enrollment":134},{"nctId":"NCT04791176","phase":"PHASE2","title":"Phase II Study of Concurrent Lenvatinib and Radiotherapy for Advanced HCC","status":"COMPLETED","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2021-04-12","conditions":"Hepatocellular Carcinoma, Radiotherapy, Lenvatinib","enrollment":64},{"nctId":"NCT03609359","phase":"PHASE2","title":"Lenvatinib and Pembrolizumab Simultaneous Combination Study","status":"COMPLETED","sponsor":"National Cancer Center Hospital East","startDate":"2018-10-03","conditions":"Advanced Gastric Cancer","enrollment":29},{"nctId":"NCT06041477","phase":"PHASE3","title":"Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-10-31","conditions":"Hepatocellular Carcinoma, Chemotherapy Effect, Chemotherapeutic Toxicity","enrollment":540},{"nctId":"NCT06389422","phase":"PHASE2","title":"Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thrombosis","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2024-05-01","conditions":"Hepatocellular Carcinoma, Radiotherapy, Pembrolizumab","enrollment":30},{"nctId":"NCT06364007","phase":"PHASE2","title":"HAIC Combined With Durvalumab and Tremelimumab and Lenvatinib in uHCC","status":"RECRUITING","sponsor":"Sulai Liu","startDate":"2024-03-03","conditions":"Hepatocellular Carcinoma","enrollment":20},{"nctId":"NCT06233981","phase":"PHASE2","title":"Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor Thrombosis","status":"UNKNOWN","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2024-01-25","conditions":"Hepatocellular Carcinoma, Radiotherapy, Tislelizumab","enrollment":30},{"nctId":"NCT02199392","phase":"PHASE1","title":"A Pharmacokinetic Study to Assess the Influence of P-glycoprotein Inhibition and Simultaneous CYP3A4 and P-glycoprotein Induction on E7080 Pharmacokinetics Following Single Dose Oral Administration of 24 mg E7080 to Healthy Volunteers","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2011-11","conditions":"P-glycoprotein, Healthy Volunteers","enrollment":15},{"nctId":"NCT02198170","phase":"PHASE1","title":"A Pharmacokinetic Study to Assess the Influence of Simultaneous CYP3A4 and P-glycoprotein Inhibition on E7080 Pharmacokinetics Following Single Dose Oral Administration of 5 mg E7080 to Healthy Volunteers","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2011-02","conditions":"Healthy Volunteers","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Concurrent targeted therapy"],"phase":"phase_3","status":"active","brandName":"Concurrent Lenvatinib","genericName":"Concurrent Lenvatinib","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lenvatinib is a multi-targeted tyrosine kinase inhibitor that blocks FGFR, VEGFR, RET, and KIT signaling to inhibit tumor angiogenesis and growth. Used for Advanced hepatocellular carcinoma (in combination therapy), Differentiated thyroid cancer, Renal cell carcinoma (in combination therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}